Chronic Idiopathic Constipation Therapeutic Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class (Bulk-Forming Agents, Emollients, Laxatives, Osmotic Agents), By Route of Administration (Oral, Parenteral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region and Competition, 2020-2030F

Market Overview

Global Chronic Idiopathic Constipation Therapeutic Market was valued at USD 11.53 Billion in 2024 and is expected to reach USD 13.89 Billion by 2030 with a CAGR of 6.11% during the forecast period. The Global Chronic Idiopathic Constipation Therapeutic Market refers to the worldwide industry dedicated to the development, production, and distribution of therapeutic treatments for chronic idiopathic constipation (CIC). CIC is a common gastrointestinal disorder characterized by infrequent and difficult bowel movements of unknown cause. This market encompasses various pharmaceuticals and therapies aimed at alleviating the symptoms and improving the quality of life for individuals suffering from CIC. Awareness campaigns and improved diagnostic tools have played a pivotal role in identifying individuals with CIC. More people are recognizing the symptoms and seeking medical advice, leading to earlier diagnosis and treatment. This heightened awareness has driven the demand for CIC therapeutic options.

Key Market Drivers

Rising Prevalence of CIC

Chronic Idiopathic Constipation (CIC) is a prevalent gastrointestinal disorder characterized by infrequent and difficult bowel movements of unknown origin. It is a condition that affects millions of people globally and significantly impacts their quality of life. According to a cohort study published by the American College of Gastroenterology in November 2023, the prevalence of chronic idiopathic constipation (CIC) in the United States is 6.0%, while opioid-induced constipation (OIC) stands at 1.7%.

In recent years, the rising prevalence of CIC has emerged as a driving force behind the growth of the Global CIC Therapeutic Market. The first and foremost factor contributing to the growth of the CIC therapeutic market is the escalating prevalence of this condition. More and more individuals are being diagnosed with CIC, which can be attributed to various lifestyle changes, dietary habits, and demographic shifts.

As the global population ages, the likelihood of experiencing CIC increases. Elderly individuals are particularly susceptible to this condition due to age-related changes in their digestive systems. With an aging demographic worldwide, the demand for CIC therapeutic solutions is on the rise. Modern lifestyles characterized by sedentary behavior and unhealthy dietary choices have also contributed to the surge in CIC cases. A lack of physical activity and insufficient fiber intake can lead to constipation, and these lifestyle factors have become more prevalent in many parts of the world. 

CIC can have a significant negative impact on an individual's quality of life, leading to discomfort, distress, and reduced productivity. As people prioritize their overall well-being, there is a growing emphasis on finding effective treatments for CIC, further propelling the market's growth. Pharmaceutical companies are investing heavily in research and development to create innovative and more effective CIC therapies. This includes prescription medications, over-the-counter remedies, and biological treatments. These advancements provide patients with a wider range of options, increasing the market's attractiveness. Healthcare providers are increasingly adopting a patient-centric approach to care, recognizing the individual needs and preferences of patients. This approach tailors treatment plans to suit each patient, ensuring better outcomes and patient satisfaction.

Growing Aging Population

The global population is aging, and with this demographic shift comes an increase in various health challenges. Among these, Chronic Idiopathic Constipation (CIC) stands out as a condition that disproportionately affects the elderly. This aging population is becoming a significant catalyst for the growth of the Global Chronic Idiopathic Constipation Therapeutic Market. The aging of the world's population is a well-documented phenomenon. Improved healthcare, nutrition, and lifestyle factors have led to longer life expectancy. In 2022, the United Nations Department of Economic and Social Affairs (UNDESA) reported that 771 million individuals were aged 65 or older. This figure is projected to rise to 994 million by 2030 and 1.6 billion by 2050.  This demographic shift is creating new healthcare challenges, and CIC is one such challenge.

As individuals age, various physiological changes occur in the body, including those in the digestive system. These changes can lead to an increased risk of constipation. Reduced motility in the gastrointestinal tract, decreased muscle tone, and altered sensory perception of the rectum are common factors contributing to constipation in the elderly. Consequently, the elderly are more likely to develop CIC. CIC can severely impact the quality of life for older individuals. Chronic constipation often leads to discomfort, pain, and complications such as hemorrhoids and fecal impaction. It can also exacerbate other age-related health issues. Given the desire for a comfortable and fulfilling life in their later years, elderly individuals and their healthcare providers are increasingly seeking solutions for CIC.

The growing awareness of CIC among healthcare providers and the elderly themselves has led to an increased demand for therapeutic options. The aging population is more proactive about seeking medical care and advocating for their health, which has created fertile ground for the development and marketing of CIC therapeutics. Pharmaceutical companies recognize the lucrative potential of the aging demographic in relation to CIC. According to data published in June 2023 by the American Gastroenterological Association (AGA) and the American College of Gastroenterology (ACG), chronic idiopathic constipation (CIC) affects between 8% and 12% of the U.S. population. Symptoms of CIC include infrequent bowel movements, incomplete evacuation, and difficulty passing stools. However, unlike other forms of constipation, the underlying cause of CIC remains unknown. As a result, they are investing in research and development to create innovative medications and therapies specifically tailored to the needs of the elderly population. These therapies aim to address the unique challenges and concerns associated with CIC in older adults. The economic implications of a growing aging population cannot be overlooked. Governments and healthcare systems are increasingly recognizing the importance of addressing conditions that affect the elderly, including CIC. As a result, funding, research, and regulatory support for CIC therapeutics are on the rise. In April 2022, Ardelyx Inc. received approval from the United States Food and Drug Administration (USFDA) for IBSRELA, an NHE3 inhibitor designed to treat irritable bowel syndrome with constipation (IBS-C) in adults. The increasing prevalence of irritable bowel syndrome and constipation, coupled with growing initiatives from key market players, is expected to drive market growth in the region.

Download Free Sample Report

Key Market Challenges

Long-Term Treatment Needs

Chronic Idiopathic Constipation (CIC) is a lifelong condition, meaning that the therapeutic solutions required to manage it need to be sustained over extended periods, often for a patient's entire life. This inherent long-term aspect creates several obstacles, particularly in terms of patient adherence to prescribed treatments. Over time, individuals may experience treatment fatigue, leading to decreased motivation to continue with therapy. This is especially true for patients who may not see immediate improvements or may feel discouraged by the prolonged nature of the treatment. In addition, long-term treatments may involve complex regimens that can be difficult for patients to follow consistently. Healthcare professionals must employ strategies to enhance adherence, including personalized treatment plans, patient education, and regular monitoring. The challenge is compounded by financial constraints, as ongoing therapy may place a significant economic burden on patients, making affordability and insurance coverage key concerns. This issue requires a multifaceted approach, including more accessible and cost-effective treatment options, along with supportive care to ensure sustained management of the condition.

Management of Side Effects

Pharmaceutical interventions for CIC, such as laxatives, prokinetic agents, or fiber supplements, often come with side effects ranging from mild symptoms, like bloating and abdominal discomfort, to more serious complications such as dehydration or electrolyte imbalances. This creates a delicate balancing act for healthcare providers, as the primary goal is to alleviate constipation symptoms without introducing new health issues through the side effects of treatment. Some therapies, such as prescription medications, may have more severe side effects that discourage continued use. Consequently, providers must work to tailor treatments for individual patients, carefully monitoring the onset of any adverse effects while attempting to find the most effective therapy. This can involve regular adjustments to medications or doses, which can be time-consuming and challenging. The complexity of balancing symptom relief with side effect management also means that CIC treatment often requires a more proactive and personalized approach, adding to the resource strain on healthcare providers and increasing the cost of treatment for patients.

Addressing Underlying Causes

CIC is classified as idiopathic, meaning that its exact causes are not fully understood. This presents a significant challenge for healthcare professionals who must manage the condition without a clear etiology. Unlike constipation resulting from known causes such as gastrointestinal disorders or certain medications, CIC's origins are obscure, making it difficult to target and treat the root cause effectively. As a result, therapeutic interventions primarily focus on alleviating symptoms, without necessarily addressing the underlying factors contributing to the condition. This can limit the long-term effectiveness of treatments, as patients may continue to experience symptoms or require increasing dosages of therapies to manage their condition. In addition, a lack of understanding about the causes of CIC may hinder the development of targeted therapies that could offer more effective solutions in the future. To overcome this challenge, further research is needed to uncover the underlying mechanisms of CIC and improve treatment options. This could lead to more personalized therapies that not only alleviate symptoms but also address the root causes of the disorder, improving the long-term prognosis for patients.

 Key Market Trends

Rise in Awareness and Diagnosis

In the realm of healthcare, awareness and timely diagnosis are powerful drivers of progress. This holds especially true for Chronic Idiopathic Constipation (CIC), a widespread gastrointestinal disorder that affects millions worldwide. The growth of the Global Chronic Idiopathic Constipation Therapeutic Market is intimately tied to the increasing awareness of CIC and improvements in diagnosis. Chronic Idiopathic Constipation, often abbreviated as CIC, is characterized by persistent constipation without an identifiable underlying cause. While a common condition, CIC can have a significant negative impact on an individual's quality of life. This condition can lead to discomfort, pain, and complications, making effective treatments all the more crucial. In May 2022, EA Pharma and Mochida Pharmaceutical introduced MOVICOL HD, a treatment for chronic constipation, in Japan. MOVICOL enhances water retention within the digestive system, increases stool moisture, softens stool volume, stimulates colonic peristalsis, and facilitates defecation.

One of the primary factors driving the growth of the CIC therapeutic market is the heightened awareness of this condition. Awareness campaigns, patient education initiatives, and healthcare provider training have all contributed to improved understanding and recognition of CIC. As more people become aware of the symptoms and potential risks of CIC, they are more likely to seek medical assistance. Today's patients are increasingly empowered when it comes to their healthcare decisions. With easy access to information, individuals are more proactive about their health. As a result, people experiencing CIC symptoms are more likely to consult healthcare professionals, thereby driving the demand for therapeutic options.  Accurate diagnosis is essential for effective management and treatment of CIC. Advances in diagnostic tools, including more precise imaging techniques and the development of clinical guidelines, have made it easier for healthcare providers to diagnose CIC. Early and accurate diagnosis enables timely intervention and enhances the likelihood of successful treatment outcomes.

Awareness and diagnosis are not only beneficial for patients but also attractive to pharmaceutical companies. As the demand for CIC treatments grows, pharmaceutical firms are investing in research and development to create innovative therapeutics. These efforts have resulted in the development of a wider range of medications and therapies, including prescription drugs and over-the-counter remedies, tailored to meet the needs of patients diagnosed with CIC. CIC is a condition that knows no geographical boundaries. It affects people worldwide. As awareness and diagnosis efforts expand globally, the CIC therapeutic market has a broader reach, offering opportunities for pharmaceutical companies to reach diverse patient populations.

Advancements in Pharmaceutical Research

Pharmaceutical research has long been at the forefront of medical innovation, and its impact on healthcare continues to be profound. One area where these advancements are notably making a difference is in the Global Chronic Idiopathic Constipation (CIC) Therapeutic Market. CIC is a common gastrointestinal disorder characterized by infrequent and difficult bowel movements of unknown cause. It significantly impairs the quality of life for those affected and is a condition that demands effective treatment options. Advancements in pharmaceutical research represent a powerful driving force behind the growth of the CIC therapeutic market. This includes research into new medications, treatment modalities, and a better understanding of the underlying mechanisms of CIC.

The CIC therapeutic market has seen a substantial expansion of treatment options thanks to pharmaceutical innovation. These options range from traditional laxatives to prescription medications and more novel approaches like prokinetics and biological therapies. These advancements provide healthcare providers and patients with a broader array of choices to address CIC. Pharmaceutical research has led to the development of therapies that are not only more effective but also safer for patients. Modern CIC treatments are designed to provide symptom relief without significant side effects, enhancing patient compliance and satisfaction.

One of the most exciting developments in CIC therapeutics is the emergence of biological therapies. These treatments target specific pathways and mechanisms involved n gastrointestinal function. They offer a more precise and targeted approach to treating CIC, promising enhanced efficacy. Advancements in pharmaceutical research have facilitated a shift towards personalized medicine. Healthcare providers can now tailor treatment plans to individual patient needs, ensuring that CIC therapies are optimized for each patient's unique circumstances.

Drug Class Insights

Based on the category of Drug Class, Bulk-forming agents are poised to secure a substantial market share in the Global Chronic Idiopathic Constipation Therapeutic Market during the forecast period for several compelling reasons. The increasing prevalence of chronic idiopathic constipation across the globe has driven the demand for effective and safe therapeutic solutions. Bulk-forming agents, with their ability to promote regular bowel movements by adding bulk to stool and enhancing overall gastrointestinal function, are increasingly preferred by both healthcare professionals and patients. Furthermore, these agents are well-tolerated, with minimal side effects, making them a preferred choice for long-term management. Additionally, the growing awareness of the importance of preventive healthcare and the trend towards natural and non-pharmacological remedies have further bolstered the adoption of bulk-forming agents. As a result, their significant market presence is expected to persist and even expand during the forecast period, solidifying their position as a vital component of the chronic idiopathic constipation therapeutic market.

Distribution Channel Insights

Hospital pharmacies are poised to capture a substantial market share in the Global Chronic Idiopathic Constipation Therapeutic Market during the forecast period for several compelling reasons. Firstly, hospitals serve as critical hubs for the diagnosis and treatment of chronic idiopathic constipation, providing a centralized point for patient care. The convenience and accessibility of hospital pharmacies make them a preferred choice for healthcare professionals to procure and dispense therapeutic solutions promptly. Moreover, hospitals often stock a wide range of pharmaceutical products, including specialized medications for chronic constipation, thereby meeting the diverse needs of patients. Additionally, the increasing burden of chronic idiopathic constipation worldwide is leading to a higher number of patients seeking care in hospitals, further boosting the demand for therapeutic options available through hospital pharmacies. Overall, the strategic position of hospital pharmacies as integral components of the healthcare system positions them to witness significant market share growth in the chronic idiopathic constipation therapeutic market during the forecast period.

Download Free Sample Report

Regional Insights

North America is poised to dominate the Global Chronic Idiopathic Constipation Therapeutic Market for several compelling reasons. The region boasts a robust healthcare infrastructure with advanced medical facilities and a well-established pharmaceutical industry. This enables timely diagnosis and treatment of chronic idiopathic constipation, resulting in a higher demand for therapeutic solutions. Additionally, a growing aging population in North America, which is more susceptible to chronic constipation, contributes significantly to market growth. Furthermore, the region has a high level of awareness among both healthcare professionals and patients regarding the importance of effective constipation management, leading to a greater adoption of therapeutic options. Moreover, North America is home to several key players in the pharmaceutical industry who continuously innovate and develop new treatments, thereby expanding the market further. In conclusion, the combination of a robust healthcare system, demographic factors, and industry expertise positions North America to dominate the Global Chronic Idiopathic Constipation Therapeutic Market.

Recent Developments

• In March 2024, Sanofi Consumer Health formed a partnership with Alliance Healthcare and Phoenix Healthcare Distribution to distribute its products to pharmacies throughout the United Kingdom. This collaboration enables Sanofi Consumer Healthcare to improve operational efficiency, expand its product offerings, and increase the availability of Allevia, Buscopan, Dulcolax, and Phenergan across the country.
• In January 2024, Bayer AG's consumer health division launched "The Gut Gap" campaign in the United States to raise awareness about the high prevalence of stress and constipation among American women. The brand-commissioned survey was conducted to expand the reach of MiraLax for constipation treatment in the U.S. market.
• In June 2023, the FDA approved Linzess as the first treatment for pediatric functional constipation in patients aged 6 to 17 years. The supplemental new drug application for Linzess (linaclotide 72 µg, AbbVie/Ironwood), which was previously approved for the treatment of adults with irritable bowel syndrome with constipation or chronic idiopathic constipation, received an early Prescription Drug User Fee Act date of June 14—approximately four months ahead of the standard review cycle timeline.
• In June 2023, the American Gastroenterological Association and the American College of Gastroenterology introduced new guidelines for the treatment of chronic idiopathic constipation. The updated guidelines highlight 10 evidence-based methods for managing constipation, including magnesium oxide and senna-based laxatives.
• In June 2024, new Phase 3 data reaffirmed the safety and efficacy of linaclotide for pediatric functional constipation. The latest findings from a Phase 3 study of linaclotide (Linzess) in pediatric patients aged 6-17 with functional constipation offer further insights into its effectiveness in this patient group and provide additional support for its U.S. Food and Drug Administration (FDA) approval for this indication.

Key Market Players

• GSK PLC
• Astellas Pharma Inc
• Synergy Pharmaceuticals Inc.
• Bayer AG
• Allergan PLC
• Sanofi SA
• Pfizer Inc
• Takeda Pharmaceutical Co Ltd
• Zydus Lifesciences Ltd
• Boehringer Ingelheim GmbH

Report Scope:

In this report, the Global Chronic Idiopathic Constipation Therapeutic Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Chronic Idiopathic Constipation Therapeutic Market, By Drug Class:

o   Bulk-Forming Agents

o   Emollients

o   Laxatives

o   Osmotic Agents

• Chronic Idiopathic Constipation Therapeutic Market, By Route of Administration:

o   Oral

o   Parenteral

• Chronic Idiopathic Constipation Therapeutic Market, By Distribution Channel:

o   Hospital Pharmacies

o   Retail Pharmacies

o   Online Pharmacies

• Chronic Idiopathic Constipation Therapeutic Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  Germany

§  United Kingdom

§  France

§  Italy

§  Spain

o   Asia-Pacific

§  China

§  Japan

§  India

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Chronic Idiopathic Constipation Therapeutic Market.

Available Customizations:

Global Chronic Idiopathic Constipation Therapeutic market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Chronic Idiopathic Constipation Therapeutic Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]